Ever present hurdles for the discovery of new drugs for cancer therapy have necessitated
the development of the alternative strategy of drug repurposing, the development of old …

Awareness that the metabolic phenotype of cells within tumours is heterogeneous—and
distinct from that of their normal counterparts—is growing. In general, tumour cells …

High rates of failure, exorbitant costs, and the sluggish pace of new drug discovery and
development have led to a growing interest in repurposing “old” drugs to treat both common …

In the era of precision medicine, cancer therapy can be tailored to an individual patient
based on the genomic profile of a tumour. Despite the ever-increasing abundance of cancer …

Copper (Cu) plays a pivotal role in cancer progression by acting as a co-factor that regulates
the activity of many enzymes and structural proteins in cancer cells. Therefore, Cu-based …

PubMed® is an essential resource for the medical domain, but useful concepts are either
difficult to extract or are ambiguous, which has significantly hindered knowledge discovery …

The repositioning or “repurposing” of existing therapies for alternative disease indications is
an attractive approach that can save significant investments of time and money during drug …

Resistance to cancer therapy remains a major challenge in clinical oncology. Although the
initial treatment phase is often successful, eventual resistance, characterized by tumour …

Drug screening—ie, testing the effects of a number of drugs in multiple cell lines—is used for
drug discovery and development, and can also be performed to evaluate the heterogeneity …

Highlights•Drug repositioning and similar terms have been a trending topic since
2004.•From a legal or regulatory perspective stimulation of drug repositioning requires …